The NCI Community Oncology Research Program (NCORP) is a national network of cancer care investigators, providers, academia, and other organizations that care for diverse populations in health systems.
The DCP Community Oncology and Prevention Trials Research Group administers this program.
On this page
About NCORP
The program brings cancer clinical trials and control and delivery studies to individuals in their own communities, thereby generating a broadly applicable evidence base that contributes to improved patient outcomes and a reduction in cancer disparities.
Grantee Details
No matching Grants were found.
Clinical Trials
| Title Sort descending | Intervention | Sponsor | Status |
|---|---|---|---|
| Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer | Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration | Gary Morrow | Completed |
| Radiation Therapy in Treating Patients With Prostate Cancer | 36.25 Gy IMRT, 51.6 Gy IMRT | Radiation Therapy Oncology Group | Completed |
| Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy | Trastuzumab, Whole Breast Irradiation, Laboratory Biomarker Analysis | National Cancer Institute (NCI) | Active, not recruiting |
| Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program | Health Promotion and Education, Informational Intervention, Questionnaire Administration, Smoking Cessation Intervention | Alliance for Clinical Trials in Oncology | Recruiting |
| Reproductive Health Program in Patients With Cancer | Standard practice related to reproductive heath, Training modules, algorithm, referral development | ECOG-ACRIN Cancer Research Group | Active, not recruiting |
| S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000 | selenium, selenium placebo, vitamin E, vitamin E placebo | SWOG Cancer Research Network | Completed |
| S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases | assessment of therapy complications | SWOG Cancer Research Network | Completed |
| S0820, Adenoma and Second Primary Prevention Trial | Eflornithine placebo & sulindac, Eflornithine placebo & sulindac placebo, Eflornithine plus sulindac, eflornithine & sulindac placebo | SWOG Cancer Research Network | Active, not recruiting |
| S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride | assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment | SWOG Cancer Research Network | Completed |
| S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer | Text message reminder | SWOG Cancer Research Network | Completed |